drugset / Trial / NCT03688061
Class II Invariant Chain HCV Vaccine Study
Phase 1
Completed
25 enrolled
University of Oxford
European Commission · collabGlaxoSmithKline · collabOxford University Hospitals NHS Trust · collabReiThera Srl · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients.
Timeline
- Start
- 2017-12-04
- Primary completion
- 2019-08-04
- Completion
- 2022-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChAd3-hliNSmut | Vaccine | 5e+09 unknown | Intramuscular |
| Subject | ChAd3-hliNSmut | Vaccine | 2.5e+10 unknown | Intramuscular |
| Subject | MVA-hliNSmut | Vaccine | 5e+07 unknown | Intramuscular |
| Subject | MVA-hliNSmut | Vaccine | 2e+08 unknown | Intramuscular |